Skip to main content
. Author manuscript; available in PMC: 2019 May 1.
Published in final edited form as: Hum Immunol. 2017 Nov 22;79(5):258–265. doi: 10.1016/j.humimm.2017.11.008

Table 2.

The summary of QOL study.

Characteristics Tolerant group (n = 5) Conventional group (n = 32) P value
Complications –No. of events (%) .33
Malignancy 0 4 (11.8) .41
Infection 2 (40.0) 14 (43.8) .62
Medications after transplant -% patients .002
Hypertension 20 78.1 .004
Dyslipidemia 0 40.6 .07
Diabetes requiring insulin 0 12.5 .40
QOL measure Tolerant group (n = 5) Conventional group (n = 16)
Kidney transplant-targeted scales
Burden of kidney transplantation 98.75 ± 11.27 70.70 ± 30.50 .04
Sexual function 100 70.83 ± 33.07 .04
36-item health survey scales
Physical function 98.89 ± 2.48 73.95 ± 31.6 .04
General health 76.00 ± 6.52 51.87 ± 28.33 .04
Social function 100 70.31 ± 32.87 .03
Energy/fatigue 72.00 ± 5.70 52.50 ± 21.21 .04
Overall health 90.00 ± 7.07 66.87 ± 23.30 .01
Symptom occurrence (mean % occurrence) Tolerant group (n = 5) Conventional group (n = 16)
Depressed 0 32.14 .001
Excessive appetite 0 30.36 .006
Flatulence 0 17.86 .04
Healing loss 0 21.43 .04
Increased thirst 6.25 35.71 .04
Itching 0 17.86 .04
Joint pain 0 23.21 .02
Lack of energy 12.5 32.14 .04
Muscle cramps 0 17.86 .02
Reduced libido 0 28.57 .04
Shortness of breath 0 17.86 .02